JP2018528200A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528200A5
JP2018528200A5 JP2018510406A JP2018510406A JP2018528200A5 JP 2018528200 A5 JP2018528200 A5 JP 2018528200A5 JP 2018510406 A JP2018510406 A JP 2018510406A JP 2018510406 A JP2018510406 A JP 2018510406A JP 2018528200 A5 JP2018528200 A5 JP 2018528200A5
Authority
JP
Japan
Prior art keywords
ring
independently
acceptable salt
cycloalkyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018510406A
Other languages
English (en)
Japanese (ja)
Other versions
JP6877407B2 (ja
JP2018528200A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/048698 external-priority patent/WO2017035354A1/en
Publication of JP2018528200A publication Critical patent/JP2018528200A/ja
Publication of JP2018528200A5 publication Critical patent/JP2018528200A5/ja
Application granted granted Critical
Publication of JP6877407B2 publication Critical patent/JP6877407B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018510406A 2015-08-26 2016-08-25 Ntrk関連障害の治療に有用な化合物および組成物 Expired - Fee Related JP6877407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210264P 2015-08-26 2015-08-26
US62/210,264 2015-08-26
PCT/US2016/048698 WO2017035354A1 (en) 2015-08-26 2016-08-25 Compounds and compositions useful for treating disorders related to ntrk

Publications (3)

Publication Number Publication Date
JP2018528200A JP2018528200A (ja) 2018-09-27
JP2018528200A5 true JP2018528200A5 (OSRAM) 2019-09-12
JP6877407B2 JP6877407B2 (ja) 2021-05-26

Family

ID=56896780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510406A Expired - Fee Related JP6877407B2 (ja) 2015-08-26 2016-08-25 Ntrk関連障害の治療に有用な化合物および組成物

Country Status (17)

Country Link
US (2) US10017512B2 (OSRAM)
EP (1) EP3341374A1 (OSRAM)
JP (1) JP6877407B2 (OSRAM)
KR (1) KR20180043810A (OSRAM)
CN (1) CN108137607B (OSRAM)
AR (1) AR105836A1 (OSRAM)
AU (1) AU2016311426B2 (OSRAM)
BR (1) BR112018003588A2 (OSRAM)
CA (1) CA2995997A1 (OSRAM)
HK (1) HK1255330A1 (OSRAM)
IL (1) IL257702A (OSRAM)
MX (1) MX2018002407A (OSRAM)
PH (1) PH12018500397A1 (OSRAM)
RU (1) RU2744974C2 (OSRAM)
TW (1) TW201713665A (OSRAM)
WO (1) WO2017035354A1 (OSRAM)
ZA (1) ZA201801881B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
BR112016008541B1 (pt) 2013-10-17 2022-11-22 Blueprint Medicines Corporation Composto ou sal farmaceuticamente aceitável, uso do mesmo para tratar mastocistose, tumor do estroma gastrointestinal e leucemia, e composição farmacêutica
AU2014339972B9 (en) 2013-10-25 2019-05-30 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
KR20180048635A (ko) 2015-07-24 2018-05-10 블루프린트 메디신즈 코포레이션 Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물
RU2744974C2 (ru) 2015-08-26 2021-03-17 Блюпринт Медсинс Корпорейшн Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk
IL302209B2 (en) 2015-11-02 2024-06-01 Blueprint Medicines Corp Inhibitors of ret
CA3005741A1 (en) 2015-11-19 2017-05-26 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
EP4285996A3 (en) 2016-04-15 2024-01-10 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN113735881A (zh) 2017-08-23 2021-12-03 正大天晴药业集团股份有限公司 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途
CN111566102B (zh) 2017-10-18 2023-09-08 缆图药品公司 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶
CN111936138B (zh) * 2018-02-05 2024-03-08 深圳市原力生命科学有限公司 作为ep4受体拮抗剂的杂二环化合物
CN111971287B (zh) * 2018-03-28 2023-06-02 重庆复尚源创医药技术有限公司 作为trk激酶抑制剂的大环化合物
PT3773589T (pt) 2018-04-03 2024-02-06 Blueprint Medicines Corp Inibidor de ret para utilização no tratamento de cancro com alteração de ret
KR20220012221A (ko) * 2019-02-27 2022-02-03 페로 테라퓨틱스 인코포레이티드 페롭토시스 유도 활성을 갖는 화합물 및 이의 사용 방법
EP3856341B1 (en) 2019-04-12 2023-09-06 Blueprint Medicines Corporation Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
JP7787812B2 (ja) * 2019-11-25 2025-12-17 アルカームス インコーポレーテッド 置換大環状化合物および関連する治療方法
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CN113408945B (zh) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 一种烤烟纯度的检测方法、装置、电子设备及存储介质

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014450A1 (en) * 1996-10-02 1998-04-09 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
PL224879B1 (pl) 2002-09-04 2017-02-28 Pharmacopeia Drug Discovery Inc Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
EP2168968B1 (en) * 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US8076338B2 (en) * 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
TR201807039T4 (tr) 2008-10-22 2018-06-21 Array Biopharma Inc Trk kinaz inhibitörleri olarak sübstitüe edilmiş pirazolo[1,5-]pirimidin bileşikleri.
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2566866A1 (en) * 2010-05-05 2013-03-13 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
US20150218652A1 (en) * 2012-08-31 2015-08-06 The Regents Of The Unversity Of Colorado, A Body Corporate Methods for diagnosis and treatment of cancer
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ, インコーポレイテッド Gdf−8阻害剤
HK1214830A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型ntrk1融合分子及其应用
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
HK1222173A1 (zh) * 2013-02-01 2017-06-23 Bayer Pharma Aktiengesellschaft 取代的吡唑并嘧啶基氨基-吲唑类
CN103965199B (zh) 2013-02-02 2017-07-07 广东东阳光药业有限公司 一种芳杂环化合物、包含它的药物组合物及其用途
ES2674705T3 (es) 2013-02-21 2018-07-03 Calitor Sciences, Llc Compuestos heteroaromáticos como moduladores de la quinasa PI3
EP2970307B1 (en) 2013-03-13 2020-03-11 Genentech, Inc. Pyrazolo compounds and uses thereof
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
BR112016008541B1 (pt) 2013-10-17 2022-11-22 Blueprint Medicines Corporation Composto ou sal farmaceuticamente aceitável, uso do mesmo para tratar mastocistose, tumor do estroma gastrointestinal e leucemia, e composição farmacêutica
AU2014339972B9 (en) 2013-10-25 2019-05-30 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2015157093A1 (en) 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
HRP20240937T1 (hr) 2014-12-15 2024-10-25 Cmg Pharmaceutical Co., Ltd. Heteroaril spoj sa kondeziranim prstenom i njihova primjena kao trk inhibitora
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
WO2016133838A1 (en) 2015-02-20 2016-08-25 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
KR20180048635A (ko) 2015-07-24 2018-05-10 블루프린트 메디신즈 코포레이션 Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물
RU2744974C2 (ru) 2015-08-26 2021-03-17 Блюпринт Медсинс Корпорейшн Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk
IL302209B2 (en) 2015-11-02 2024-06-01 Blueprint Medicines Corp Inhibitors of ret
CA3005741A1 (en) 2015-11-19 2017-05-26 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
EP4285996A3 (en) 2016-04-15 2024-01-10 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
US20190192522A1 (en) 2016-09-08 2019-06-27 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors
CN107844168B (zh) 2017-11-23 2020-12-01 英业达科技有限公司 主板组件及其卡扣装置

Similar Documents

Publication Publication Date Title
JP2018528200A5 (OSRAM)
RU2018110379A (ru) Соединения и композиции, применяемые для лечения расстройств, связанных с ntrk
JP2013544807A5 (OSRAM)
JP2013541561A5 (OSRAM)
JP2014520898A5 (OSRAM)
JP2010501572A5 (OSRAM)
JP2013522292A5 (OSRAM)
JP2017537080A5 (OSRAM)
FI4355749T3 (fi) Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja
EA201391324A1 (ru) Бис(фторалкил)-1,4-бензодиазепиноновые соединения
BR112014027190A2 (pt) pirrolobenzodiazepinas
JP2019535720A5 (OSRAM)
JP2019514863A5 (OSRAM)
JP2019514955A5 (OSRAM)
PH12017502334A1 (en) Polycyclic amide derivative as cdk9 inhibitors
UY32251A (es) Compuestos quimicos
WO2016160617A3 (en) Inhibitors of cyclin-dependent kinases
WO2016105528A3 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2015506985A5 (OSRAM)
JP2013502423A5 (OSRAM)
CA2593428A1 (en) Pyrrolopyrazoles, potent kinase inhibitors
RU2012105914A (ru) Эффективные низкомолекулярные ингибиторы аутофагии и способ их применения
JP2020531481A5 (OSRAM)
EA201001126A1 (ru) Пирролопиримидины и пирролопиридины
JP2020097631A5 (OSRAM)